TB-500 Compounding Pharmacy: 503A vs 503B, What Every Patient Needs to Know

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Does TB-500 have a legal pathway through a compounding pharmacy today?

Not under the current FDA lists. For state-licensed pharmacies and physicians that compound, a bulk drug substance must meet one of three conditions: it complies with an applicable USP or National Formulary monograph; it is a component of an FDA-approved drug product where no monograph exists; or it appears on FDA's bulks list for those compounders [4]. TB-500 meets none of the three. FDA's July 2026 review found no USP or National Formulary monograph for it and no FDA-approved drug containing it [1], and TB-500 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026 [2].

Compounding through those channels also requires that the bulk substance be accompanied by a valid certificate of analysis and have been manufactured by an establishment registered with FDA under section 510 of the Food, Drug, and Cosmetic Act [4]. These are additional requirements on top of the three routes above.

Outsourcing facilities work from a separate list, and TB-500 appears in none of its three categories, updated March 21, 2025 [3]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1]. A separate HHS draft policy, covered below, addresses enforcement but does not change these lists.

How the two compounding routes differ

A state-licensed compounder is a pharmacy, federal facility or licensed physician. FDA's interim policy sorts nominated bulk substances into three groups: category 1, where FDA says it does not intend to take action against a compounder if the policy's conditions are met; category 2, where FDA has identified significant safety risks and does not extend that policy; and category 3, nominated with too little information to evaluate [4]. TB-500 is not in any of the three on the list for state-licensed pharmacies [2].

An outsourcing facility registers with FDA, and FDA publishes a list showing each facility's registration dates, last inspection, whether a Form 483 was issued, and whether a recall was conducted [10]. Nothing in FDA's TB-500 record shows an outsourcing facility producing or reporting a TB-500 product [1].

Why FDA staff recommended against adding TB-500

In a July 2026 briefing document, FDA staff proposed that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulks list [1]. The stated reasons: the substance is not well characterized, with inconsistent naming and no impurity, aggregate or endotoxin data; its historical use is unclear; there is no evidence of effectiveness for wound healing, the use FDA evaluated; injectable peptides carry an immunogenicity risk; and FDA-approved wound treatments already exist [1].

FDA's page on bulk substances that may raise significant safety risks lists 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in its 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them [7]. FDA's concerns there are that it has not identified any human exposure data on drug products containing the fragment, that it lacks important safety information, and that injectable peptides may pose an immunogenicity risk from aggregation and peptide-related impurities [7]. Removal from category 2 was not a finding that TB-500 is safe [7].

What the July 2026 advisory committee vote did and did not change

FDA's Pharmacy Compounding Advisory Committee reviewed TB-500-related substances on July 23, 2026, alongside BPC-157, KPV and MOTS-C, with wound healing as the use FDA evaluated [8]. The committee voted in favor of adding TB-500 to the bulks list, against FDA staff's recommendation [8][5]. Advisory committee recommendations are non-binding [8]. TB-500 is not on the list, and adding it requires formal rulemaking [5].

The October 2026 HHS draft policy

HHS filed a draft enforcement-discretion policy for compounding with certain peptides on October 28, 2026, scheduled for Federal Register publication on October 30, 2026, with comments due two weeks after publication [5]. It names six peptides, TB-500 among them, and it covers TB-500 acetate given by subcutaneous or intramuscular injection [5][6].

Under the draft, HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with TB-500 if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [5][6].

The notice itself says it 'does not establish any rights for any person and is not binding on HHS or the public,' and HHS may revisit it, for example if a safety signal or product quality issue arises [5]. It is not an FDA approval and does not put TB-500 on any list [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [5].

What is known about TB-500 in humans

Very little. FDA searched PubMed, Embase, ClinicalTrials.gov and other sources and found no article in which TB-500 was given to a human, and none of the three papers the nominator cited involved TB-500 in humans [1]. In an in-vitro scratch-wound test, TB-500 at 50 microgram/mL did not induce wound closure in fibroblast cultures; a shorter metabolite, N-acetylated LKKTE, did show activity in vitro [1].

There are no human pharmacokinetic or pharmacodynamic data for TB-500 by any route [1]. Animal studies indicate that TB-500 given subcutaneously or intraperitoneally reaches the bloodstream and is broken down into smaller peptides, and FDA found no animal studies by intramuscular injection [1].

On safety, an FDA adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and FDA's food and supplement complaint system retrieved two cases about a blended TB-500 and BPC-157 product, with no safety assessment [1]. FDA found no published case reports, and safety in humans is unknown [1]. FDA's BPC-157 review describes one 40-year-old woman who used a 'research purposes only' BPC-157 plus TB-500 (5 mg/5 mg) injection subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, which recurred when she re-tried the product two weeks later; because the product held two peptides, FDA said it cannot tell whether either caused it [11].

Human trials exist for a different molecule. In a first-in-human phase 1 study of recombinant full-length human thymosin beta-4, 54 healthy volunteers entered the single-dose trial and 30 entered the multiple-dose trial, and participants received thymosin beta-4 or placebo; adverse events were mild to moderate, with no dose-limiting toxicity or serious adverse events [12]. That study used the 43-amino-acid protein, not the 7-amino-acid fragment, and did not test TB-500 [1][12].

Does WADA prohibit TB-500?

Yes. WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3, growth factors and growth factor modulators, and it is prohibited at all times, in and out of competition [9]. It is on the 2026 List in force since January 1, 2026 and stays on the 2027 List [9][13].

What to make of TB-500 sellers' claims

TB-500 is sold online as a 'research use only' injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157, and a veterinary preparation appeared in 2011 marketed for horses and greyhounds [1]. A seller describing it as FDA-approved, as legal to compound, or as cleared by the 2026 advisory committee vote is wrong on all three points: the committee advised and FDA staff recommended against listing, and the HHS policy is a non-binding draft [8][5][1].

Bulk substances used by state-licensed pharmacies must come with a valid certificate of analysis and be manufactured by an FDA-registered establishment [4], and the draft HHS policy repeats the certificate-of-analysis and registered-manufacturer conditions for TB-500 acetate [5]. The draft policy also lists a single active ingredient among its conditions, so a vial blending TB-500 with BPC-157 would not fit that condition [5].